Shanghai Biolaxy gets Chinese approval for oral insulin project, Nodlin
Thursday, November 26, 2009 16:00 IST Shanghai
Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes.